Triptans


Study Exclusion reasons Rmk Reference
Ephross (all treated), 2014 inadequate or absent control group PV registry of GlaxoSmithKline.

Ephross SA Headache 2014;54:1158-72 10.1111/head.12375

Yusuf (all treated), 2018 inadequate or absent control group This study was funded by Amgen and was conceived and conducted by Amgen employees.

Yusuf Pharmacoepidemiol Drug Saf 2018; 27:1309-1315 10.1002/pds.4658

Fiore (PV data - Rizatriptan only), 2005 inadequate or absent control group

Fiore Cephalalgia 2005; 25:685-8 10.1111/j.1468-2982.2004.00929.x

Wilton (no control group), 1998 inadequate or absent control group

Wilton Br J Obstet Gynaecol 1998; 105:882-9 10.1111/j.1471-0528.1998.tb10234.x

Illoh, 2018 other reason

Illoh Pharmacoepidemiol Drug Saf 2018; 27:604-611 10.1002/pds.4409

Harris, 2017 other reason

Harris BMC Pregnancy Childbirth 2017; 17:224 10.1186/s12884-017-1399-0

Banhidy, 2007 not relevant exposure

Banhidy Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 134:157-63 10.1016/j.ejogrb.2006.08.025

Cunnington, 2009 repeat population groups, duplicate reports (most recent study included)

Cunnington M Headache 2009;49:1414-22 10.1111/j.1526-4610.2009.01529.x

Nezvalova-Henriksen, 2010 repeat population groups, duplicate reports (most recent study included)

Nezvalova-Henriksen Headache 2010; 50:563-75 10.1111/j.1526-4610.2010.01619.x

Källén, 2003 repeat population groups, duplicate reports (most recent study included)

Källén Reprod Toxicol. 2003 May-Jun;17(3):255-61. 10.1016/S0890-6238(03)00012-1

Wood 2016c, 2016 same data already obtained by other studies

Wood ME BMJ Open 2016;6:e011971 10.1136/bmjopen-2016-011971